Ophthalmic drugs during pregnancy
Keywords:
Ophthalmic drugs. Pregnancy. Fetal risk.Abstract
The information available on the safety of medicines in pregnant women is limited and must be suitably channeled. Medication that is applied topically or as eye drops can present relevant systemic absorption and cross the placenta barrier or enter maternal milk.
We have reviewed ophthalmic medicines according to the fetal risk categories proposed by the classification of the Food and Drug Administration (FDA). We evaluate the medicines of choice in the most frequent ophthalmic pathologies, as well as the medicines that must be avoided.
Downloads
References
1. ABAD FJ, PONS J, MICÓ M, CASTERÁ DE, BELLÉS MD, SÁNCHEZ A. Categorías de riesgo de los medicamentos utilizados durante el embarazo: Guía rápida de consulta. FAP 2005; 3: 49-61.
2. YANG T, WALKER MC, KREWSKI D, YANG Q, NIMROD C, GARNER P et al. Maternal characteristics associated with pregnancy exposure to FDA category C, D and X drugs in a Canadian population. Pharmacoepidemiol Drug Saf 2008; 17: 270-277.
https://doi.org/10.1002/pds.1538
3. BARBERÁ E, VÁZQUEZ F. Tratamientos tópicos oculares: revisión. Inf Ter Sist Nac Salud 2009; 33: 80-87.
4. GIL MR, ORTEGA J, GIL MT, CORTÉS C. Farmacología ocular durante la gestación y la lactancia (I). Studium ophthalmologicum 2010; 28: 59-66.
5. DENIS D, TOUVRON G. Conduite à tenir chez une patiente présentant un glaucome pendant la grossesse. J Fr Ophtalmol 2010; 33: 346-349.
https://doi.org/10.1016/j.jfo.2010.03.007
6. RAZEGHINEJAD MR, TANIA TAI TY, FUDEMBERG SJ, KATZ LJ. Pregnancy and glaucoma. Surv Ophthalmol 2011; 56: 324-35.
https://doi.org/10.1016/j.survophthal.2010.11.008
7. WAGENVOORT A.M, VAN VUGT J.M.G, SOBOTKA M, VAN GEIJN H.P. Topical timolol therapy in pregnancy: is it safe for the fetus ? Teratology 1998; 58: 258-262.
https://doi.org/10.1002/(SICI)1096-9926(199812)58:6<258::AID-TERA7>3.0.CO;2-B
8. MADADI P, KOREN G, FREEMAN DJ, OERTEL R, CAMPBELL RJ, TROPE GE. Timolol concentrations in breast milk of a woman treated for glaucoma. Calculation of neonatal exposure. J Glaucoma 2008; 17: 329-331.
https://doi.org/10.1097/IJG.0b013e31815c3a5b
9. COPPENS G, STALMANS I, ZEYEN T. Glaucoma medication during pregnancy and nursing. Bull Soc Belge Ophtalmol 2010; 314: 33-36.
10. DING C, LU M, HUANG J. Changes of the ocular surface and aquaporins in the lacrimal glands of rabbits during pregnancy. Mol Vis 2011; 17: 2847-2855.
11. ESTEBAN E. Fármacos anti-VEGF (vascular endothelial growth factor). En: Arias L. Actualización de terapia anti-VEGF en enfermedades de la retina y coroides. Barcelona: Elsevier España, 2010: 1-5.
https://doi.org/10.1016/B978-84-8086-706-1.50001-8
12. GIL MR, ORTEGA J, GIL MT, CORTÉS C. Farmacología ocular durante la gestación y la lactancia (II). Studium ophthalmologicum 2010; 28: 121-128.
13. LÓPEZ MJ, SÁNCHEZ JI, SÁNCHEZ MC, CALDERAY M. Suplementos en embarazadas: controversias, evidencias y recomendaciones. Inf Ter Sist Nac Salud 2010; 34: 117-128.
14. LABETOULLE M, GENDRON G, OFFRET H. Les collyres chez l'enfant et la femme enceinte ou allaitante: quelles difficultés et pourquoi? J Fr Ophtalmol 2009; 32: 135-150.
https://doi.org/10.1016/j.jfo.2008.12.003
15. MILLODOT M. The influence of pregnancy on the sensitivity of the cornea. Br J Ophtalmol 1977; 61: 646-649.
https://doi.org/10.1136/bjo.61.10.646
16. WEINREB RN, LU A, BEESON C. Maternal corneal thickness during pregnancy. Am J Ophtalmol 1988; 105: 258-260.
https://doi.org/10.1016/0002-9394(88)90006-2
17. CHUNG CY, KWOK AKH, CHUNG KL. Use of ophthalmic medications during pregnancy. Hong Kong Med J 2004; 10: 191-195.
18. SHINOMIYA K, KAJIMA M, TAJIKA H, SHIOTA H, NAKAGAWA R, SAIJYOU T. Renal failure caused by eyedrops containing phenylephrine in a case of retinopathy of prematurity. J Med Invest 2003; 50: 203-206.
19. GASSET AR, AKABOSHI T. Embryopathic effect of ophthalmic EDTA. Invest Ophtalmol Vis Sci 1977; 16: 652-654.
Published
How to Cite
Issue
Section
License
Copyright (c) 2014 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
